Sickle cell disease and pregnancy outcomes: Population-based study on 8.8 million births

Journal of Perinatal Medicine

Volumn 42, Issue 4, 2014, Pages 487-492

  Alayed, Nada ^a,b   Kezouh, Abbas ^a   Oddy, Lisa ^a   Abenhaim, Haim A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b 5790 Cote Des Neiges ^*  (Canada)

Author keywords

Outcomes; Pregnancy; Sickle cell disease

Indexed keywords

HEMOGLOBIN VARIANT;

ADULT; ARTICLE; CARDIOMYOPATHY; CESAREAN SECTION; CHILDBIRTH; COHORT ANALYSIS; ECLAMPSIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL MORTALITY; MORBIDITY; POPULATION RESEARCH; PREECLAMPSIA; PREGNANCY OUTCOME; PRENATAL GROWTH; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SICKLE CELL ANEMIA; VENOUS THROMBOEMBOLISM; ANEMIA, SICKLE CELL; COMPLICATION; DELIVERY; FETAL GROWTH RETARDATION; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; ANEMIA, SICKLE CELL; COHORT STUDIES; DELIVERY, OBSTETRIC; FEMALE; FETAL GROWTH RETARDATION; HUMANS; MATERNAL DEATH; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84904173096     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/jpm-2013-0275     Document Type: Article

References (15)

1. Chaube S, Murphy ML. The effects of hydroxyurea and related compounds on the rat fetus. Cancer Res. 1966;26:1448-57.
2. Desesso JM, Jordan RL. Drug induced limb dysplasias in fetal rabbits. Teratology. 1977;15:199-211.
3. Hassell KL. Population estimates of sickle cell disease in the US. Am J Pref Med. 2010;38:S512-S21.
4. HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2007-2009. Agency for Healthcare Research and Quality R, MD. [cited 2013 July 1] www.hcup-us. ahrq.gov/nisoverview.jsp.
5. Howard J, Oteng-Ntim E. The obstetric management of sickle cell disease. Best Pract Res Clin Obstet Gynecol. 2012;26: 25-36.
6. Howard RJ, Tuck SM, Pearson TC. Pregnancy in sickle cell disease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. BJOG: An Int J Obstet Gynaecol. 1995;102: 947-51. (Pubitemid 26014988)
7. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194:1311-5.
8. Kobak AJ, Stein PJ, Daro AF. Sickle-cell anemia in pregnancy. A review of the literature and report of six cases. Am J Obstet Gynecol. 1941;41:811-23.
9. Murphy ML, Chaube S. Preliminary survey of hydroxyurea (NSC-32065) as a teratogen. Cancer chemotherapy reports Part 1. 1964;40:1.
10. Naik RP, Streiff MB, Haywood Jr C, Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013;126:443-9.
11. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease-life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-44.
12. Sun PM, Wilburn W, Raynor BD, Jamieson D. Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet Gynecol. 2001;184:1127-30. (Pubitemid 32434263)
13. Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol. 2008;199:125.e1-5.
14. Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115:2354-63.
15. Wilson NO, Ceesay FK, Hibbert JM, Driss A, Obed SA, Adjei AA, et al. Pregnancy Outcomes among Patients with Sickle Cell Disease at Korle-Bu Teaching Hospital, Accra, Ghana: Retrospective Cohort Study. Am J Trop; Med Hyg. 2012;86: 936-42.